Special AT-rich sequence-binding protein 2 (SATB2) mRNA (SATB2 mRNA)

Special AT-rich sequence-binding protein 2 (SATB2) is a nuclear matrix-associated transcription factor that plays a pivotal role in organizing chromatin architecture and regulating gene expression (UniProt Q9UPW6). It is essential for the development of the craniofacial skeleton and the specification of upper-layer neurons in the cerebral cortex (NCBI Gene 23314). Clinically, haploinsufficiency of SATB2 results in SATB2-associated syndrome, a multisystem disorder characterized by intellectual disability, severe speech delay, and cleft palate (OMIM 608148). In the field of oncology, SATB2 serves as a robust diagnostic biomarker for colorectal cancer, as its expression is largely restricted to the lower gastrointestinal tract (PubMed: 22016035). While there are currently no FDA-approved drugs targeting SATB2 mRNA, it is an area of active research for RNA-based therapeutics, such as siRNAs and microRNAs, particularly in the context of suppressing its oncogenic potential in certain bone and brain tumors (PubMed: 28651318). Therapeutic strategies focusing on the mRNA transcript aim to modulate protein levels in diseases where SATB2 is either overexpressed or where its function is deleterious.

Other names

SATB homeobox 2 mRNAGLSS mRNASpecial AT-rich sequence-binding protein 2 transcriptDNA-binding protein SATB2 mRNA

RNA interference (RNAi) or antisense oligonucleotide (ASO) mediated knockdown of the SATB2 transcript to modulate protein expression levels.